Gastrointestinal microbiota and metabolite biomarkers in children with autism spectrum disorders.
Autism spectrum disorder (ASD) is a neurodevelopmental disorder. Many affected individuals also display symptoms of gastrointestinal (GI) disturbance, suggesting GI factors may play an important role in the pathogenesis of ASD and/or related complications. The current review will focus on evidence supporting a role for the GI microbiota and their fermentation products in the etiology and/or symptoms of ASD, and their potential use as biomarkers. GI-related biomarkers could potentially enable early identification of ASD at risk of GI disturbance, and thereby guide targeted interventions, potentially improving the health and quality of life of affected individuals.
Sansom Institute for Health Research, University of South Australia, GPO Box 2471, Adelaide, SA 5001, Australia.
Lv
L
Wang
Michael Allan
MA
Conlon
Claus Thagaard
CT
Christophersen
Michael Joseph
MJ
Sorich
Manya Therese
MT
Angley
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism*; D002659:Child Development Disorders, Pervasive / Q000150:complications / Q000378:metabolism* / Q000473:pathology; D003013:Clostridium / Q000302:isolation & purification; D003248:Constipation / Q000150:complications / Q000188:drug therapy; D003967:Diarrhea / Q000150:complications / Q000188:drug therapy; D041981:Gastrointestinal Tract / Q000382:microbiology*; D006801:Humans; D064307:Microbiota; D019936:Probiotics / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D015415:Biomarkers